New Cholesterol Guidelines: A Shift Towards Proactive Heart Health
The American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly released an updated guideline for screening and managing blood cholesterol levels, the first major update since 2018. Published in the Journal of the American College of Cardiology and Circulation, the guideline emphasizes earlier screenings, personalized risk estimations, and a focus on lowering LDL cholesterol – often called “bad” cholesterol – to prevent heart attacks, strokes, and heart failure.
Earlier Screening & Personalized Risk Assessment
A key change in the new guideline is a call for earlier screenings, particularly for individuals with a family history of heart disease or underlying medical conditions. For those with familial hypercholesterolemia, inherited high LDL-C levels, screening should begin in childhood, around age 9 or even earlier. The guideline also recommends a one-time screening for lipoprotein(a) (Lp(a)), a genetically influenced lipid that can significantly increase heart disease risk.
Understanding Lp(a) and its Impact
Elevated levels of Lp(a) can increase a person’s risk for heart disease by as much as 40% at levels of 125 nanomoles per liter, and double that risk at 250 nanomoles per liter. This highlights the importance of considering genetic predispositions when assessing cardiovascular risk.
New Risk Calculation Tools
The updated guideline introduces a new risk calculator, PREVENT (Predicting Risk of Cardiovascular Disease EVENTs), to estimate 10- and 30-year risks for heart attacks, and stroke. PREVENT incorporates data on blood sugar and kidney health, offering a more comprehensive assessment than the previously used pooled cohort equation, and is recommended for leverage starting at age 30.
Beyond LDL: The Role of Inflammation and Calcium Scoring
The guideline also acknowledges the importance of “risk enhancers” – factors that can refine risk assessment beyond traditional cholesterol levels. These include assessing inflammation levels with a high-sensitivity C-reactive protein (hsCRP) test, considering Lp(a) elevation, and evaluating family history of early cardiovascular disease. Coronary artery calcium (CAC) scanning, which detects calcium deposits in the arteries, is also recommended to personalize treatment decisions.
Treatment Considerations for Specific Populations
The updated guideline provides specific recommendations for treatment decisions in diverse populations, including pregnant or lactating women, adults age 75 and older, and individuals with conditions like diabetes, kidney disease, or HIV. It also addresses treatment strategies for those undergoing cancer therapy.
Modern Lipid-Lowering Therapies
The guideline details the use of statin therapy and other lipid-lowering treatments, such as ezetimibe, bempedoic acid, and PCSK9 monoclonal antibody treatments. These newer therapies are particularly valuable for individuals who don’t respond adequately to statins or require more aggressive LDL-C lowering.
Optimal LDL-C Levels
For individuals without cardiovascular disease, optimal LDL-C levels are considered below 100 mg/dL. Those with intermediate risk should aim for levels below 70 mg/dL, while individuals with higher risk should strive for levels below 55 mg/dL. The guideline also provides recommendations for non-HDL-C and apolipoprotein B.
The Foundation of Heart Health: Lifestyle Interventions
Despite advancements in medical treatments, the guideline reinforces the importance of foundational heart-healthy habits: a balanced diet, regular physical activity, avoiding tobacco, sufficient sleep, and maintaining a healthy weight. Approximately 80-90% of cardiovascular disease is linked to modifiable risk factors, making lifestyle interventions a crucial first step.
Future Trends in Cardiovascular Prevention
The release of this guideline, alongside research like the VESALIUS-CV trial demonstrating benefits of aggressive LDL-C lowering, signals a growing trend towards proactive and personalized cardiovascular prevention. Future guidelines are likely to further emphasize lower LDL-C targets, potentially recommending levels below 55 mg/dL for individuals with established atherosclerosis.
FAQ
Q: What is LDL cholesterol?
A: Low-density lipoprotein (LDL) cholesterol, often called “bad” cholesterol, can build up in the arteries and increase the risk of heart disease.
Q: Who should be screened for high cholesterol?
A: The new guideline recommends earlier screenings, especially for those with a family history of heart disease or underlying medical conditions.
Q: What is Lp(a)?
A: Lipoprotein(a) is a genetically influenced lipid that can significantly increase heart disease risk. A one-time screening is now recommended.
Q: What is the PREVENT score?
A: PREVENT is a new risk calculator that estimates the risk of heart attack and stroke, incorporating data on blood sugar and kidney health.
Q: What role does lifestyle play in heart health?
A: Lifestyle interventions, such as diet and exercise, are crucial for preventing cardiovascular disease and should be a foundational approach.
Did you know? Lowering LDL cholesterol levels can significantly reduce the risk of heart attacks, strokes, and congestive heart failure.
Pro Tip: Discuss your family history and risk factors with your doctor to determine the appropriate screening schedule and treatment plan for you.
Learn more about cholesterol and heart health at hopkinsmedicine.org and hopkinsmedicine.org.
What are your thoughts on the new cholesterol guidelines? Share your comments below!
